Zoetis Inc. (LON: 0M3Q)
Market Cap | 59.15B |
Revenue (ttm) | 6.83B |
Net Income (ttm) | 1.81B |
Shares Out | n/a |
EPS (ttm) | 3.97 |
PE Ratio | 32.63 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | Jan 21, 2025 |
Volume | 4 |
Open | 164.50 |
Previous Close | 165.14 |
Day's Range | 164.50 - 164.50 |
52-Week Range | 151.44 - 201.92 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Feb 14, 2025 |
About Zoetis
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives... [Read more]
Financial Performance
In 2023, Zoetis's revenue was $8.54 billion, an increase of 5.74% compared to the previous year's $8.08 billion. Earnings were $2.34 billion, an increase of 10.88%.
Financial numbers in USD Financial StatementsNews
Zoetis dips as FDA cites adverse events linked to canine pain therapy Librela
Zoetis (ZTS) stock falls as FDA notifies about adverse events in dogs treated with the company's pain therapy Librela. Read more here.
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
Zoetis (NYSE: ZTS) has outperformed the market over the past 10 years by 4.24% on an annualized basis producing an average annual return of 15.83%. Currently, Zoetis has a market capitalization of $8...
Zoetis raises quarterly dividend by 16% to $0.50/share
Zoetis Declares First Quarter 2025 Dividend; Board Approves 16% Payment Increase
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the first quarter of 2025, an increase of 16% ...
Zoetis: Are Competition And Price Increases A Cause For Concern?
Zoetis is the market leader in a growing industry, and the numbers are starting to show its dominance. Click here to read an analysis of ZTS stock now.
The animal health industry is resilient, Zoetis CEO
Zoetis CEO Kristin Peck unpacks pet owners' concerns in caring for their beloved animals on 'The Claman Countdown.'
Zoetis Inc. (ZTS) Piper Sandler 36th Annual Healthcare Conference (Transcript)
How do I get out of a lease for a Renault electric car battery?
Reader says it is unfair she would have to pay £2,000 to buy the battery in her Zoe, or £400 to have it removed I own an eight-year-old Renault Zoe and lease the battery for £50 a month from Mobilize ...
My Top 15 High-Growth Dividend Stocks For December 2024
The SPDR S&P 500 ETF Trust posted a strong gain of 5.96% in November, resuming its strong run in 2024. The Top 15 dividend growth stocks for December 2024 offer an average dividend yield of 1.2% and a...
Zoetis: Healing Paws, Growing Profits
Zoetis Inc. (ZTS) Management presents at Jefferies London Healthcare Conference (Transcript)
Zoetis Inc. (NYSE:ZTS) Jefferies London Healthcare Conference November 20, 2024 10:00 AM ET Company Participants Wetteny Joseph - CFO Conference Call Participants Glen Santangelo - Jefferies Glen San...
Zoetis to Participate in the Piper Sandler 36th Annual Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024. Wetteny Joseph, E...
Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy
Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO, outperforming the S&P 500. The company benefits from increasing global pet ownership and spending...
Zoetis: The Major Player in the $500B Pet Market You May Not Have Heard Of
The pet industry is growing fast and could reach a global market size of half a trillion dollars by 2032. This episode looks at why people bought more pets during COVID, the trend of treating pets lik...
Zoetis Appoints Jamie Brannan to Newly Created Chief Commercial Officer Role
PARSIPPANY, N. J.--(BUSINESS WIRE)--ZOETIS APPOINTS JAMIE BRANNAN TO NEWLY CREATED CHIEF COMMERCIAL OFFICER ROLE.
Zoetis Q3: Strong Osteoarthritis Pain Franchise
I reiterate a 'Buy' rating for Zoetis with a one-year target price of $210 per share, driven by strong product performance and strategic divestitures. The Company's osteoarthritis drugs, LIBRELA and S...
Zoetis to Participate in Jefferies London Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Wetteny Joseph, Executi...
Zoetis Inc. (ZTS) Q3 2024 Earnings Call Transcript
Zoetis Inc. (NYSE:ZTS) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Steve Frank - VP of IR Kristin Peck - CEO Wetteny Joseph - CFO Conference Call Participants Er...
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Zoetis Inc. For Fraud
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("...
Zoetis raises annual forecasts on strong demand for pet treatments
Zoetis raised its annual profit and revenue forecasts on Monday on strong demand for its medicines and vaccines for animals.
Zoetis Announces Third Quarter 2024 Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2024 and raised its full year 2024 guidance for revenue a...
My Top 15 High-Growth Dividend Stocks For November 2024
The SPDR S&P 500 ETF Trust posted a loss of 0.89% in October, putting a pause on its strong run in 2024. The Top 15 dividend growth stocks for November 2024 offer an average dividend yield of 1.24% an...
Zoetis Inc Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("...
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Zoetis Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("...
Phibro Animal Health Corporation Completes Acquisition of Zoetis' Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) today announced the successful completion of the acquisition of the medicated feed additive product portfolio and certai...